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Background: The genetic predisposition to elite athletic performance has been a
controversial subject due to the underpowered studies and the small effect size of
identified genetic variants. The aims of this study were to investigate the association
of common single-nucleotide polymorphisms (SNPs) with endurance athlete status
in a large cohort of elite European athletes using GWAS approach, followed by
replication studies in Russian and Japanese elite athletes and functional validation using
metabolomics analysis.
Results: The association of 476,728 SNPs of Illumina DrugCore Gene chip and
endurance athlete status was investigated in 796 European international-level athletes
(645 males, 151 females) by comparing allelic frequencies between athletes specialized
in sports with high (n = 662) and low/moderate (n = 134) aerobic component.
Replication of results was performed by comparing the frequencies of the most
significant SNPs between 242 and 168 elite Russian high and low/moderate aerobic
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athletes, respectively, and between 60 elite Japanese endurance athletes and 406
controls. A meta-analysis has identified rs1052373 (GG homozygotes) in Myosin Binding
Protein (MYBPC3; implicated in cardiac hypertrophic myopathy) gene to be associated
with endurance athlete status (P = 1.43 × 10−8, odd ratio 2.2). Homozygotes carriers
of rs1052373 G allele in Russian athletes had significantly greater VO2max than carriers
of the AA + AG (P = 0.005). Subsequent metabolomics analysis revealed several
amino acids and lipids associated with rs1052373 G allele (1.82 × 10−05) including
the testosterone precursor androstenediol (3beta,17beta) disulfate.
Conclusions: This is the first report of genome-wide significant SNP and related
metabolites associated with elite athlete status. Further investigations of the functional
relevance of the identified SNPs and metabolites in relation to enhanced athletic
performance are warranted.
Keywords: GWAS, SNP, metabolomics, metabolites, elite athletes, endurance
BACKGROUND
Elite athletic performance is a multi-factorial trait with input
from both genetic and environmental factors. The superior
performance of elite athletes has been historically considered
an outcome of a special talent shaped by intensive training.
The talent is now believed to be a product of additive genetic
components predisposing the athlete to endurance, speed,
strength, flexibility and coordination trainability under the
control of strong environmental cues including exercise and
nutrition. In this model, the genetic predisposition together with
ability to respond to training are the keys to the superior physical
performance of elite athletes (Georgiades et al., 2017).
Sports can be classified according to the type and intensity
of the exercise required to perform during competition. The
percentage of maximal oxygen uptake (VO2max) is a detrimental
factor in the categorization of endurance sports, as it reflects
the maximal cardiac output, the oxygen transport capacity,
and the blood volume (Bergh et al., 2000). Accordingly, sports
can be divided into sport events with low, moderate and high
aerobic (dynamic) component (Mitchell et al., 2005). Similarly,
the percent of maximal voluntary contraction (MVC), which
reflects the greatest amount of tension a muscle can generate and
hold, is used to classify sports into sporting disciplines with low,
moderate and high power component (Mitchell et al., 2005).
Classical twin and family genetic studies have suggested
that VO2max is up to 94% inherited (Bouchard et al., 1998;
Peeters et al., 2009). Genome-wide association studies (GWAS)
in athletes versus non-athletes have uncovered many new
loci in association with VO2max (Rankinen et al., 2010;
Abbreviations: ACP2, acid phosphatase 2, Lysosomal; ADLQ, anti-doping
laboratories in Qatar; FDR, false discovery rate; FMSI, Laboratorio Antidoping,
Federazione Medico Sportiva Italiana; GVS, genome variation server; GWAS,
genome-wide association studies; HESI-II, high resolution/accurate mass
spectrometer interfaced with a heated electrospray ionization; MADD, MAP
kinase activating death domain; MAF, minor allele frequency; MVC, maximal
voluntary contraction; MYBPC3, myosin binding protein C, cardiac; NR1H3,
nuclear receptor subfamily 1 group H member 3; OR, odds ratio; Spi-1, Spi-1
proto-oncogene; UPLC, ultra-performance liquid chromatography; VO2max ,
maximal oxygen uptake.
Bouchard et al., 2011) and elite endurance performance
(Ahmetov et al., 2015). A more recent review of genetic
predisposition to elite athletic endurance has highlighted 100
endurance variants (Semenova et al., 2019). However, despite
some initial evidence suggesting identification of genetic variants
in GWAS studies, further studies did not replicate/validate
these findings hindered by a small sample size and complex
phenotype (Pitsiladis et al., 2016). One of the first GWAS in
athletes using 143 K single-nucleotide polymorphisms (SNPs)
and subsequent meta-analysis of 45 promising genetic markers
in 1,520 endurance athletes and 2,760 controls has revealed
only one statistically significant marker (rs558129 at GALNTL6)
associated with endurance status in world class athletes, but not
at genome wide level of significance (Rankinen et al., 2016).
Therefore, the genetic predisposition to endurance traits remains
unclear, largely due to the relatively underpowered elite athletes’
cohorts. Recently, a polymorphism in human homeostatic
iron regulator protein was found to be associated with elite
endurance athlete status and aerobic capacity in Russian athletes
(Semenova et al., 2020).
Metabolomics analysis has presented a novel tool to validate
genomics data by providing an intermediate phenotype
(metabolites) in association with the identified genetic
variants (Kastenmuller et al., 2015; Tanaka et al., 2016). Pilot
metabolomics studies have revealed differences in the metabolic
signature of moderate and high endurance elite athletes, such
as steroid biosynthesis, fatty acid metabolism, oxidative stress
and energy-related molecular pathways (Al-Khelaifi et al., 2018,
2019a). Recently, a study investigating metabolic GWAS of
elite athletes showed novel genetically influenced metabolites
associated with athletic performance. These included two novel
genetic loci in FOLH1 and VNN1 in association with N-acetyl-
aspartyl-glutamate and linoleoyl ethanolamide, respectively,
and one novel locus linking genetic variant in SULT2A1 and
androstenediol (3alpha, 17alpha) monosulfate in endurance
athletes (Al-Khelaifi et al., 2019b).
In this study, we aimed to investigate the association of
multiple SNPs and endurance athlete status in a relatively large
cohort of European elite athletes specialized in sports with high
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and low/moderate aerobic component using GWAS approach
and replicate our findings in elite Russian and Japanese athletes.
We also aimed to perform functional validation using VO2max
testing and metabolomics analysis by identifying metabolites that
are associated with significant endurance-related SNPs.
RESULTS
Genome-Wide Association Study
Athletes from the discovery cohort were classified into
different groups of sports following previously published
sports classification criteria (Mitchell et al., 2005), as shown
in Table 1.
The principle component analysis (PCA) of the genotyping
data revealed no influence of sport disciplines (Figure 1A)
or training modality (i.e., sports with low/moderate versus
high aerobic component) (Figure 1B) on genotype distribution.
Following quality control data processing, genotyping of
341385 SNPs in 796 European elite athletes revealed several
variants associated with endurance athlete status, but none
reached GWAS level of significance. Table 2 shows top SNPs
(P < 5 × 10−5) with their odd ratios (OR) in relation
to elite athletic endurance, location according to function
genome variation server (GVS), gene name and minor allele
frequency (MAF) in sports with high and low/moderate aerobic
component. MAF in non-elite athletes from 1,000 genome
project were used as a reference. Figure 1 shows Manhattan
(C) and quartile-quartile (QQ) plots (D) of GWAS hits
associated with endurance.
Replication of Endurance SNPs in
Russian and Japanese Elite Athlete
Cohorts
Replication of results was performed by comparing the
frequencies of the most significant SNPs (P < 10−5) in 242
elite Russian high and 168 low/moderate aerobic athletes,
and in 60 elite Japanese endurance athletes and 406 controls.
Out of the 9 top SNPs identified form the GWAS discovery
stage, the rs1052373 (MYBPC3) and rs7120118 (NR1H3)
showed significant association with endurance in Russian
and Japanese (P < 0.05). However, the association was
driven by a dominant model since results of this analysis
showed over representation for rs1052373 GG and rs7120118
TT genotypes in the high endurance group. A subsequent
meta-analysis has confirmed the over representation of
the rs1052373 GG and rs7120118 TT genotypes in high
endurance sports at genome-wide and Bonferroni levels of
significance (1.43 × 10−8 and 1.66 × 10−7, respectively)
(Table 3). The combined analysis showed no evidence of
heterogeneity and direction of association was similar in
all three cohorts.
The regional association plot for the rs1052373 G allele in
MYBPC3 gene revealed a number of SNPs in the same LD block
in association with high endurance including the rs7120118 T
allele in NR1H3 gene (Figure 2).
To validate the potential functionality of the identified
GWAS SNPs, association of the identified two SNPs (rs1052373
G and rs7120118 T alleles) with VO2max was investigated
in a subgroup of the Russian replication cohort in which
VO2max data was available. This included 32 elite Russian
long-distance athletes [19 biathletes, 13 cross-country skiers;
17 females, age 23.5 (3.5) years; 15 males, age 21.3 (4.1)
years]. The rs1052373 GG carriers had significantly greater
VO2max than carriers of the AA + AG (P = 0.005 adjusted
for sex). Similarly, rs7120118 TT carriers showed a trend of
higher VO2max than carriers of the CC + CT (P = 0.053
adjusted for sex).
For further validation of the potential functionality of the
identified GWAS SNPs, metabolomics of 750 metabolites
was carried out in a subset of the discovery cohort
(n = 490) and enriched metabolic pathways associated
with the rs1052373 G allele and rs7120118 T alleles were
determined (Table 4). Among the metabolic pathways
associated with rs56330321 and rs7120118, various lipids and
amino acids were significantly altered by their genotypes.
However, only 5alpha-androstan-3alpha,17alpha-diol
disulfate reached Bonferroni level of significance (Table 4),
exhibiting higher levels in rs1052373 GG and rs7120118
TT carriers compared to AA + AG and CC + TC carriers,
respectively (Figure 3).
DISCUSSION
Genetic predisposition into cardiorespiratory fitness and
response to exercise training has been previously described
(Lortie et al., 1982; Prud’homme et al., 1984; Hamel et al., 1986;
Bouchard et al., 1994, 1998, 1999). Since endurance performance
sports are characterized by increased cardiorespiratory capacity,
genetic predisposition into elite endurance performance
is also expected to be genetically influenced (Guth and
Roth, 2013). However, genetic studies of elite athletic
endurance showed inconsistent results (Guth and Roth,
2013; Ahmetov and Fedotovskaya, 2015; Pitsiladis et al., 2016;
Wang et al., 2016). The aims of this study were to carry
out the largest GWAS study of elite European athletes to
date using a unique SNP microarray that is enriched with
genes involved in different metabolic pathways with direct
influence on various physiological pathways characteristic
of elite athletes. GWAS results have revealed a number of
novel SNPs associated with endurance but none reached
the GWAS level of significance. Replication of the top
identified SNP associations in two independent cohorts
of elite athletes from Russia and Japan has confirmed the
association of rs7120118 and rs1052373 with endurance
athlete status. Subsequent meta-analysis of the three
cohorts has revealed for the first time that both SNPs were
associated with endurance athlete status at genome-wide
and Bonferroni level of significance, respectively. Functional
validation has revealed the association of the two SNPs with
increased Vo2max and levels of the testosterone precursor
5alpha-androstan-3alpha,17alpha-diol disulfate.
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TABLE 1 | Classification of GWAS participants according to sports classes.
Low/moderate (<70% VO2max) High (>70% VO2max) Total
High (>50% MVC) Wrestling and Judo (8M) Skate boarding (2M) Modern Pentathlon (1F) 287
Kayaking (1F) Rowing (9M/8F) Biathlon (2M/1F)
Weightlifting (14M/7F) Boxing (4M/7F) Cycling (157M/49F) Triathlon (8M/9F)
Moderate Jumping (athletics) (1F) Handball (19M/3F) Skiing Cross Country (3M/1F) Basketball (3M) 165
(20–50% MVC) Rugby (15M) Aquatics (3M/2F)
Athletics other (41M/26F) Sprint (2M) Hockey (4M/1F) Swimming (25M/16F)
Low (<20% MVC) Baseball (2M) Long-Distance running and marathon (37M/12F) Tennis (3M/3F) 344
Volleyball (2M)
Table tennis (9M) Soccer (256M/1F) Ultra-running (1F) Football (17M/1F)
134 662 796
Distribution of elite athletes in various categories based on sport type-associated peak dynamic (maximal oxygen uptake percentage; VO2max ) and peak static (maximal
voluntary muscle contraction percentage; MVC) components achieved during competition as described previously (Mitchell et al., 2005).
FIGURE 1 | GWAS data quality control. PCA shows no difference in the genotype distribution among sport disciplines (A) or between groups (sports with
low/moderate versus high aerobic component) (B) Manhattan (arrow indicates significant SNPs) (C) and Quantile-quantile (no evidence of genomic inflation, lambda
GC = 1.006) (D) plots illustrating GWAS results in association with endurance.
The top identified GWAS significant SNP (rs1052373)
is located within MYBPC3 gene. MYBPC3 codes for a
myosin-associated protein expressed in the cross-bridge-
bearing zone (C region) of A bands in striated muscle. The
phosphorylation of MYBPC3 protein modulates cardiac
contraction (Moss et al., 2015). Mutations in MYBPC3
were previously associated with a lower super-relaxed state
in patients with hypertrophic cardiomyopathy (HCM)
(McNamara et al., 2017). Intense exercise can trigger heart
remodeling to compensate for the elevations in blood pressure
or volume by increasing muscle mass. Hence, hearts of the
endurance athletes typically exhibit an eccentric cardiac
hypertrophy with increased cavity dimension and wall thickness
(Pelliccia et al., 1991; Hedman et al., 2015), which is influenced by
the type of sport performed (Pelliccia, 1996; Pelliccia et al., 1999;
Maron and Pelliccia, 2006). As a result, the endurance-trained
Frontiers in Genetics | www.frontiersin.org 4 June 2020 | Volume 11 | Article 595
fgene-11-00595 June 14, 2020 Time: 20:51 # 5
Al-Khelaifi et al. GWAS of Elite Endurance Athletes
TA
B
LE
2
|T
op
G
W
A
S
S
N
P
s
as
so
ci
at
ed
w
ith
en
du
ra
nc
e
at
hl
et
e
st
at
us
fro
m
th
e
di
sc
ov
er
y
st
ud
y.
rs
ID
C
hr
o
m
o
so
m
e
P
o
si
ti
o
n
R
ef
er
en
ce
b
as
e
N
O
R
S
ta
nd
ar
d
er
ro
r
P
va
lu
e
Fu
nc
ti
o
n
G
V
S
G
en
e
lis
t
M
A
F-
hi
g
h
ae
ro
b
ic
N
=
66
2
M
A
F-
m
o
d
er
at
e/
lo
w
ae
ro
b
ic
N
=
13
4
M
A
F-
no
n-
at
hl
et
es
rs
80
29
10
8
15
22
94
53
14
C
79
5
0.
52
93
0.
14
35
9.
23
×
10
−6
in
tr
on
C
Y
FI
P
1
0.
44
48
0.
40
3
G
=
0.
36
kg
p5
68
01
98
14
34
62
72
02
C
79
2
0.
51
51
0.
15
45
1.
75
×
10
−5
in
te
rg
en
ic
LO
C
10
27
24
94
5
0.
21
35
0.
32
46
C
=
0.
27
rs
10
83
86
81
11
47
27
50
64
A
79
4
0.
52
08
0.
15
26
1.
92
×
10
−5
in
tr
on
N
R
1H
3
0.
23
3
0.
34
96
A
=
0.
35
kg
p2
86
10
67
2
23
46
53
03
9
T
79
5
0.
22
27
0.
35
51
2.
34
×
10
−5
in
tr
on
U
G
T1
A
10
0.
01
81
5
0.
05
97
T
=
0.
01
3
kg
p1
15
12
68
4
9
12
37
98
49
2
A
79
3
0.
20
2
0.
38
08
2.
66
×
10
−5
in
tr
on
C
5
0.
01
36
4
0.
04
88
7
A
=
0.
01
6
rs
10
52
37
3
11
47
35
47
87
A
79
6
0.
53
93
0.
14
75
2.
81
×
10
−5
m
is
se
ns
e
M
Y
B
P
C
3
0.
27
64
0.
39
55
T
=
0.
39
rs
17
02
06
31
4
94
38
05
15
G
79
5
0.
30
64
0.
28
66
3.
68
×
10
−5
in
tr
on
G
R
ID
2
0.
02
87
0.
09
39
8
G
=
0.
09
rs
19
49
88
6
11
80
31
10
66
A
79
6
4.
34
6
0.
35
73
3.
92
×
10
−5
in
te
rg
en
ic
no
ne
0.
13
29
0.
03
73
1
A
=
0.
15
rs
71
20
11
8
11
47
28
62
90
C
79
6
0.
54
55
0.
14
75
3.
97
×
10
−5
in
tr
on
N
R
1H
3
0.
26
96
0.
38
81
C
=
0.
38
heart can deliver a large maximal systolic volume (35% larger
than untrained heart) in order to produce a large cardiac output
(Ogawa et al., 1992; Pelliccia et al., 1999). Since carriers of the GG
allele exhibit a benign phenotype of HCM according to NIH’s
ClinVar database (Landrum et al., 2018), the mild phenotype
may be enhancing exercise-triggered physiological adaptations.
The seemingly dominant effect of rs1052373 GG on increased
VO2max and endurance may support this added advantage
although more studies are needed to confirm this finding. These
adaptations, however, might be associated with a greater risk
of cardiovascular disease. Indeed, we have recently shown that
endurance athletes with high cardiovascular demand (higher
blood pressure and stroke volume) show metabolic signature
consistent with higher risk of cardiovascular disease (Al-Khelaifi
et al., 2019a). When investigating the expression quantitative
trait loci (eQTLs) associated with rs1052373, a number of
genes was identified including SPI1, MYBPC3, MADD, ACP2
and NR1H3 (Ray et al., 1990; Tang and Chu, 2002; Mannan
et al., 2004; Wu et al., 2012; Carrier et al., 2015; Theofilopoulos
and Arenas, 2015). Interestingly, eQTL (GTEx) showed that
rs1052373 polymorphism is associated with expression level
of MADD and ACP2 in heart, but not MYBPC3. Since MAP
kinase plays an important role of cardiac hypertrophy (Zhang
et al., 2003), the association between rs1052373 polymorphism
and VO2max and endurance may also be explained by MADD
expression, although this needs further validatoin. Information
related to function and associated diseases with these genes are
summarized in Supplementary Table S1.
The other significant association was between rs7120118
TT carriers and high endurance. Rs7120118 is located in
NR1H3 gene that codes for a nuclear receptor regulating
macrophage function, lipid homeostasis and inflammation.
NR1H3, also known as liver X Receptor Alpha (LXRA),
plays an important role in the regulation of cholesterol
homeostasis including adrenal steroidogenesis (Repa et al., 2002;
Cummins et al., 2006). The association of rs7120118 with high
endurance could be reflecting the high linkage disequilibrium
(r2 = 0.89, P < 0.0001) between rs7120118 TT and the
potentially functional rs1052373 GG. It could, however, be related
to increased synthesis of the testosterone precursor 5alpha-
androstan-3alpha,17alpha-diol disulfate since NR1H3 regulates
hypothalamo-pituitary–adrenal steroidogenesis (Handa et al.,
2011). Indeed, we have previously shown that high-endurance
athletes exhibit elevated levels of several sex hormone steroids
involved in testosterone synthesis including 5alpha-androstan-
3alpha,17alpha-diol disulfate (Al-Khelaifi et al., 2018) with
implication on improving performance due to enhanced glucose
metabolism and protein synthesis in the muscle (Sato et al.,
2008). The functional relevance of these associations remains to
be further validated.
Study limitations: The lack of information about participants
and the heterogeneity of their sport groups were major
limitations of this study. To overcome these limitations
and to increase the power of the study, genotyping was
compared between athletes who belong to high endurance
versus moderate endurance performance sports instead of
power versus endurance due to the overlap between the
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two classes as per Mitchell’s categorization (Mitchell et al.,
2005). Other limitations included using add-on replication
studies (Russian and Japanese cohorts) rather than using
a carefully designed replication. However, differences were
confirmed in each study separately and the subsequent meta-
analysis confirmed the significance of the association of the two
SNPs with endurance.
CONCLUSION
This study reports the first GWAS significant SNP (rs1052373)
in MYBPC3 in association with endurance athlete status with
a direct relevance to cardiac hypertrophy and contraction. The
SNP is associated with increased VO2max and elevated levels
of the testosterone precursor androstenediol (3beta,17beta)
disulfate, both phenotypes that potentially contribute to
the superior performance of endurance athletes. This
study also identifies a second SNP (rs7120118) associated
with endurance at Bonferroni level of significance in
NR1H3. This SNP could be either working independently
of rs1052373 through influencing steroidogenesis or could
be acting as a marker of rs1052373. Further investigations
of the functional relevance of the identified SNPs and
associated metabolites in relation to enhanced athletic
performance are warranted.
METHODS
The aim of this study is to investigate the genetic predisposition
to elite athletic endurance through conducting the largest GWAS
in elite athletes to date, followed by functional validation through
aerobic capacity testing and metabolomics analysis to shed light
on the underlying mechanisms of genetic associations.
Participants
Discovery Study
Seven hundred and ninety six consented European international-
level athletes (645 males, 151 females) from different sports
disciplines who participated in national or international
sports events and tested negative for doping substances
at anti-doping laboratories in Qatar (ADLQ) and Italy
(FMSI) were included in this study. No other information
of participants was available due to the strict anonymization
process undertaken by the anti-doping laboratories. This study
was performed in line with the World Medical Association
Declaration of Helsinki – Ethical Principles for Medical Research
Involving Human Subjects. All protocols were approved by
the Institutional Research Board of ADLQ (F2014000009).
Athletes were dichotomized into groups with different aerobic
(dynamic) and power (static) components (Table 1) based
on their sport types as described previously (Mitchell et al.,
2005). Table 1 further lists the number of participants based
on various analyses as per sport type in each class/group
and their genders.
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FIGURE 2 | Regional association plot for the region around rs1052373. The colors correspond to different LD thresholds, where LD is computed between the
sentinel SNP (lowest P-value, colored in blue) and all SNPs. Shapes of markers correspond to their functionality as described in the legend.
TABLE 4 | Metabolites that belong to the significantly enriched phospholipids pathway Top metabolites associated with significant SNPs.
SNP Beta SE.Beta P Metabolites SUPER_PATHWAY SUB_PATHWAY
rs1052373 −0.36 0.08 1.82 × 10−5 5alpha-androstan-3alpha,17alpha-diol
disulfate
Lipid Androgenic steroids
−0.25 0.07 0.000248 2-hydroxy-3-methylvalerate Amino Acid Leucine, Isoleucine and Valine Metabolism
−0.23 0.07 0.000879 alpha-hydroxyisovalerate Amino Acid Leucine, Isoleucine and Valine Metabolism
0.31 0.09 0.000928 xylose Carbohydrate Pentose Metabolism
−0.23 0.07 0.001226 N1-methylinosine Nucleotide Purine Metabolism, (Hypo)Xanthine/Inosine
containing
−0.23 0.07 0.001315 palmitoleoylcarnitine (C16:1)* Lipid Fatty Acid Metabolism(Acyl Carnitine)
−0.23 0.07 0.001509 2-hydroxyadipate Lipid Fatty Acid, Dicarboxylate
−0.22 0.07 0.001516 2-methylcitrate/homocitrate Energy TCA Cycle
−0.21 0.07 0.001933 myristoleoylcarnitine (C14:1)* Lipid Fatty Acid Metabolism(Acyl Carnitine)
rs7120118 −0.33 0.08 5.17 × 10−5 5alpha-androstan-3alpha,17alpha-diol
disulfate
Lipid Androgenic Steroids
−0.27 0.07 0.000136 2-hydroxy-3-methylvalerate Amino Acid Leucine, Isoleucine and Valine Metabolism
−0.24 0.07 0.000582 alpha-hydroxyisovalerate Amino Acid Leucine, Isoleucine and Valine Metabolism
−0.24 0.07 0.000715 N1-methylinosine Nucleotide Purine Metabolism, (Hypo)Xanthine/Inosine
containing
0.31 0.09 0.001004 xylose Carbohydrate Pentose Metabolism
−0.23 0.07 0.001527 2-hydroxyadipate Lipid Fatty Acid, Dicarboxylate
0.28 0.09 0.001966 5-acetylamino-6-formylamino-3-
methyluracil
Xenobiotics Xanthine Metabolism
−0.22 0.07 0.002116 alpha-hydroxyisocaproate Amino Acid Leucine, Isoleucine and Valine Metabolism
−0.22 0.07 0.002216 2-methylcitrate/homocitrate Energy TCA Cycle
−0.22 0.07 0.002266 glycerol Lipid Glycerolipid Metabolism
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FIGURE 3 | Boxplots representing levels of 5alpha-androstan-3alpha,17alpha-diol disulfate in rs7120118 and rs1052373 genotype groups.
Replication Studies
The first replication study involved 410 Russian athletes [187
females, age 25.3 (4.1) years, 223 males, age 25.7 (4.3) years].
Athletes were dichotomized into two groups with different
aerobic (dynamic) and power (static) components based on their
sport types. Group 1 (242 athletes with high aerobic component)
included biathletes (n = 19), cross-country skiers (n = 16), 800–
10,000 m runners (n = 9), rowers (n = 9), kayakers (n = 30),
canoers (n = 8), speed skaters (n = 12), short-trackers (n = 3),
swimmers (n = 38), cyclists (n = 5), race walkers (n = 6),
boxers (n = 43), badminton players (n = 11), basketball players
(n = 6), water polo players (n = 12), football players (n = 9),
and ice hockey players (n = 6). Group 2 (168 athletes with
low aerobic component) included 100–400 m runners (n = 8),
wrestlers (n = 44), alpine skiers (n = 2), sailors (n = 2),
synchronized swimmer (n = 1), taekwondo athletes (n = 5),
baseball players (n = 10), volleyball players (n = 19), table tennis
players (n = 5), softball players (n = 5), rhythmic gymnasts
(n = 7), chess players (n = 5), throwers (n = 6), athletics jumpers
(n = 16), ski jumpers (n = 2), weightlifters (n = 25), ure skaters
(n = 6). All athletes were Olympic team members (International
level; all Caucasians of Eastern European descent) who have
tested negative for doping substances. The Russian study was
approved by the Ethics Committee of the Federal Research and
Clinical Center of Physical-chemical Medicine of the Federal
Medical and Biological Agency of Russia. Written informed
consent was obtained from each participant. The study complied
with the guidelines set out in the Declaration of Helsinki and
ethical standards in sport and exercise science research. The
experimental procedures were conducted in accordance with
the set of guiding principles for reporting the results of genetic
association studies defined by the STrengthening the REporting
of Genetic Association studies (STREGA) Statement.
The second replication study involved endurance athletes
(n = 60) and controls (n = 406) from Japan. All endurance
athletes were track and field competitors who participated in
endurance events from 800 m to marathon. In addition, all
athletes were international athletes who had competed at major
international competitions. All controls were healthy Japanese
individuals. All subjects gave written informed consent before
their inclusion in the study. The study protocols were approved
by the ethics committee of the Juntendo University and was
conducted according to the Declaration of Helsinki.
Aerobic Capacity Testing
VO2max in biathletes and cross-country skiers was determined
using an incremental test to exhaustion on a treadmill HP
Cosmos (Germany). The initial speed was 7 km/h, the increment
was 0.1 km/h every 10 s. V˙O2max was determined breath by
breath using a MetaMax 3B-R2 gas analysis system. V˙O2max was
recorded as the highest mean value observed over a 30 s period.
Genotyping
Discovery Study
DNA was extracted from leukocytes (venous blood) samples
from all participants using DNeasy Blood & Tissue kit (Qiagen)
following manufacturer’s instructions. The concentration and the
quality of DNA were assessed using the Nanodrop (Thermo
Fisher) and Qubit Fluorometer (Invitrogen) to ensure sufficient
amount and quality of DNA were obtained for genotyping.
Illumina Drug Core array-24 BeadChips was chosen for the
genotyping of 476,728 SNPs in the 796 European elite athletes
collected for Anti-Doping analysis (discovery cohort). This
array contains over 240,000 highly-informative genome-wide
tag SNPs and a novel ∼200,000 custom marker set designed
to support studies of drug target validation and treatment
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response. The assay required 200 ng of DNA sample as input
with a concentration of at least 50 ng/µl. All further procedures
were performed according to the instructions of Infinium
HD Assay according to manufacturer’s instructions. Briefly,
4 µl of obtained DNA was mixed with Illumina amplification
reagents and incubated overnight at 37oC in hybridization
oven. On the second day, enzymatic reagents were used to
fragment the amplified DNA then precipitated by centrifugation.
Subsequently, re-suspended pellet was loaded in the beadchip
then incubated overnight at 48oC in hybridization oven. On
third day, beadchips underwent enzymatic base extension and
fluorescent staining. Lastly, after coating, the beadchips were
imaged using iScan.
Replication Studies
Molecular genetic analysis in Russian cohorts was performed
with DNA samples obtained from leukocytes (venous blood).
Four ml of venous blood were collected in tubes containing
EDTA (Vacuette EDTA tubes, Greiner Bio-One, Austria). Blood
samples were transported to the laboratory at 4◦C and DNA
was extracted on the same day. DNA extraction and purification
were performed using a commercial kit according to the
manufacturer’s instructions (Technoclon, Russia) and included
chemical lysis, selective DNA binding on silica spin columns
and ethanol washing. Extracted DNA quality was assessed
by agarose gel electrophoresis at this step. HumanOmni1-
Quad BeadChips (Illumina Inc, United States) were used for
genotyping of 1,140,419 SNPs in athletes and controls. The assay
required 200 ng of DNA sample as input with a concentration
of at least 50 ng/µl. Exact concentrations of DNA in each
sample were measured using a Qubit Fluorometer (Invitrogen,
United States). All further procedures were performed according
to the instructions of Infinium HD Assay. For the second
replication study, total DNA was isolated from saliva or venous
blood using Oragene·DNA Collection Kits (DNA genotek,
Ontario, Canada) or QIAamp DNA blood Maxi Kit (QIAGEN,
Hilden, Germany), respectively. The total DNA content was
measured using a NanoDrop 8000 spectrophotometer (Thermo
Fisher Scientific, MA, United States). Subsequently, DNA
samples were adjusted to a concentration of 50 ng/µL with
TE buffer and were stored at 4◦C. Total DNA samples were
genotyped for more than 700,000 markers using the Illumina R©
HumanOmniExpress Beadchip.
Data Extraction and SNP Identification
Raw data was extracted, peak-identified and QC processed using
Illumina iScan hardware and software. These systems are built
on a web-service platform utilizing Microsoft’s NET technologies,
which run on high-performance application servers and fiber-
channel storage arrays in clusters to provide active failover
and load-balancing.
Metabolomics
Screening of serum metabolites was performed in 490
elite athletes (Supplementary Table S2) using protocols
established at Metabolon, Durham, NC, United States. The
platform utilizes Waters ACQUITY ultra-performance liquid
chromatography (UPLC) and a Thermo Scientific Q-Exactive
high resolution/accurate mass spectrometer interfaced with a
heated electrospray ionization (HESI-II) source and Orbitrap
mass analyzer operated at 35,000 mass resolution. Detailed
protocol and QC measures were previously published (Evans
et al., 2009; Al-Khelaifi et al., 2018).
Statistical Analysis
Following genotyping using Illumina’s Drug Core SNP array,
analysis was performed using Plink v1.9. Quality control
measures were applied to the genotype data set to exclude
samples with low genotype call rate or excess heterozygosity.
Accordingly, SNPs with a genotype call rate <98%, minor
allele frequency <1%, or deviating from Hardy-Weinberg
equilibrium (P < 10−6) were excluded. After filtering the
data with the above criteria, 341,385 SNPs were used in
analysis. Population background was determined using principal
component analysis (PCA) in comparision to samples from
HapMap project and only samples with European ancestry
were included in the analysis. The analysis in European
and Russian cohorts was performed using linear or logistic
regression models. A model incorporating sports grouped by
training modalities (i.e., sports with high versus low/moderate
aerobic component) was used for the discovery cohort after
incorporating gender and PCA components 1, 2, 3 & 4 as
covariates in the model. A stringent Bonferroni level of
significance of P ≤ 0.05/341385 = 1.46 × 10−7 was used
to define significant associations. To perform the meta-
analysis, the Cochrane Review Manager version 5.3 was
used. Random and fixed effect models were applied. The
heterogeneity degree between the studies was assessed with
the I2 statistics. Associations between SNPs and metabolite
levels were computed using lm function in R (version
3.3.1) while correcting for gender, hemolysis and PCA. An
additive inheritance model was used (SNPs were coded as
0,1,2 according to their genotype group. Pathway enrichment
analyses were carried out using Chi square tests to identify
pathways with enriched metabolites ranked by P-value
from the linear model since Bonferroni level of significance
was not observed.
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